Publications by authors named "M Cork"
Attenuated total reflection (ATR) Fourier transform infrared spectroscopy (FT-IR) is used to characterize a vast array of materials at the molecular level in various industry types. Here we compare the performance of a portable spectrometer with a novel three-bounce-two-pass (3B2P) ATR scanning interface to the same device with a standard one-bounce (1B) ATR, and to a benchtop spectrometer with a 10-bounce (10B) ATR, in ideal sample-interface conditions and an applied dermatological study setting. In both application settings, the benchtop 10B ATR interface showed the highest signal-to-noise ratio (SNR), however, the novel 3B2P produced a six-fold increase in the sensitivity of the portable spectrometer when analyzing isopropanol and showed the greatest consistency of SNR of all devices when analyzing isopropanol and in vivo skin samples.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess long-term infection rates in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) treated with the medication dupilumab.
- It analyzed data from an ongoing open-label extension (OLE) study, showing that long-term dupilumab treatment resulted in lower infection rates compared to previous shorter trials.
- The findings indicate that dupilumab treatment is associated with a reduced frequency of infections and is considered safe for young children with AD.
In a randomized phase 2b trial (NCT03703102) for adult patients with moderate-to-severe atopic dermatitis (AD), treatment with the T cell rebalancing anti-OX40 receptor antibody rocatinlimab (AMG 451/KHK4083) led to significant improvements in clinical measurements versus placebo including whole-body Eczema Area and Severity Index (EASI) score. AD manifestations can impact variable anatomic regions, and involvement of the head and neck, a sensitive, hard-to-treat area, can negatively impact quality of life. In this post hoc analysis, we investigated response to rocatinlimab treatment across anatomic regions, including the head and neck.
View Article and Find Full Text PDFArticle Synopsis
- Moderate-to-severe atopic dermatitis (AD) significantly affects both children and their caregivers, prompting the study of dupilumab's impacts on symptoms and quality of life (QoL).
- In a study involving children aged 6 months to 5 years, dupilumab was compared to a placebo over 16 weeks, showing notable improvements in caregiver-reported AD symptoms and QoL as early as week 4.
- The results indicated that dupilumab not only helped alleviate AD symptoms in young patients but also enhanced the overall well-being of their caregivers and families.
Background: Janus kinase inhibitors (JAKi) have the potential to alter the landscape of atopic dermatitis (AD) management dramatically, owing to promising efficacy results from phase III trials and their rapid onset of action. However, JAKi are not without risk, and their use is not appropriate for all patients with AD, making this a medication class that dermatologists should understand and consider when treating patients with moderate-to-severe AD.
Objectives: To provide a consensus expert opinion statement from the International Eczema Council (IEC) that provides a pragmatic approach to prescribing JAKi, including choosing appropriate patients and dosing, clinical and laboratory monitoring and advice about long-term use.